The latest trading day saw AbbVie (ABBV) settling at $190.58, representing a +2.25% change from its previous close.
ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
ABBV hits a bullish golden cross as Skyrizi and Rinvoq drive growth, offsetting Humira losses and aesthetic headwinds.
![]() ABBV 3 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 6 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 9 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 15 Jul 2024 Paid | Quarterly | $1.55 Per Share |
![]() ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
23 Jul 2025 (In 1 week) Date | | 3.22 Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
![]() ABBV 3 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 6 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 9 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 15 Jul 2024 Paid | Quarterly | $1.55 Per Share |
![]() ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
23 Jul 2025 (In 1 week) Date | | 3.22 Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Robert A. Michael CPA CEO | BCBA Exchange | US00287Y1091 ISIN |
US Country | 55,000 Employees | 15 Apr 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.